FDA grants fast track designation for diffuse intrinsic pontine glioma treatment
The U.S. Food and Drug Administration has granted fast track designation for OKN-007 (Oblato, Inc) for diffuse intrinsic pontine glioma (DIPG), according to a press release.
DIPG is a rare pediatric brainstem cancer with a 5-year survival of less than 1%.
“We anticipate that the fast track designation for DIPG will shorten the NDA review process. The [Oblato] will make every effort to develop this treatment for this rare pediatric disease,” said an official from Oblato in the press release.
Read the full press release here.
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809